JinMatrix Obtains European Certification for New Molecular Diagnostic Products for Tuberculosis and Nontuberculous Mycobacteria

[Asia Economy Reporter Lee Gwanju] JinMatrix announced on the 8th that it has obtained the European medical device certification (CE-IVD) for its new respiratory diagnostic product, the 'Neoplex TB/NTM-5 Detection Kit.'

JinMatrix's new product is a PCR-based molecular diagnostic product that simultaneously differentiates one type of Mycobacterium tuberculosis and five types of nontuberculous mycobacteria. Unlike existing products that test culture media, it can quickly and accurately differentiate a total of six types of tuberculosis-related bacteria using human sputum.

Tuberculous pulmonary disease is one of the infectious diseases prioritized by the World Health Organization (WHO), along with AIDS and malaria, with more than 10 million patients worldwide every year.

In particular, nontuberculous mycobacterial pulmonary disease is difficult to treat due to high antibiotic resistance, and without appropriate treatment, it can lead to death, making species-specific customized diagnosis and treatment essential.

A JinMatrix official said, “Neoplex is an innovative product that can accurately differentiate Mycobacterium tuberculosis and nontuberculous mycobacteria in the difficult-to-diagnose and treat pulmonary disease field, while quantitatively measuring the amount of pathogens to monitor treatment effectiveness. We will continue to introduce new products that meet clinical demands to enhance competitiveness in the respiratory pathogen diagnostic sector, where demand is increasing in the global diagnostic market.”